Ceftolozane-tazobactam - Revision history

Aidan: Text replacement - " species]]" to "]]"

2022-01-28T16:28:35Z

Text replacement - " species]]" to "]]"

← Older revision		Revision as of 16:28, 28 January 2022
Line 18:		Line 18:
	**Not active against carbapenemase-producing organisms		**Not active against carbapenemase-producing organisms
	**Limited activity against Oxa-48		**Limited activity against Oxa-48
	**Limited activity against [[Acinetobacter ~~species~~]] and [[Stenotrophomonas maltophilia]]		**Limited activity against [[Acinetobacter]] and [[Stenotrophomonas maltophilia]]
	*GPC: possibly active against Strep pneumo and pyogenes, but none against Staph and Enterococcus		*GPC: possibly active against Strep pneumo and pyogenes, but none against Staph and Enterococcus
	*Variable against anaerobes		*Variable against anaerobes

Aidan at 19:07, 24 November 2021

2021-11-24T19:07:26Z

← Older revision		Revision as of 19:07, 24 November 2021
Line 34:		Line 34:
	*Urinary tract and intraabdominal infection: ceftolozane-tazobactam 1.5 g (1 g / 0.5 g) IV q8h		*Urinary tract and intraabdominal infection: ceftolozane-tazobactam 1.5 g (1 g / 0.5 g) IV q8h
	*Pneumonia: ceftolozane-tazobactam 3 g IV q8h		*Pneumonia: ceftolozane-tazobactam 3 g IV q8h
			*Multi-drug-resistant [[Pseudomonas aeruginosa]]:
			**[[Cystitis]]: 1.5 g IV q8h infused over 1 h
			**Other infections: 3 g IV q8h infused over 3 hours

	==Safety==		==Safety==

Aidan: /* Acitivity */

2020-09-15T00:46:05Z

Acitivity

← Older revision		Revision as of 00:46, 15 September 2020
Line 13:		Line 13:

	*GNB:		*GNB:
	**MDRPsA with less affinity for ~~Pseudomonal~~ AmpC and less affected by efflux and porins		**MDRPsA with less affinity for pseudomonal AmpC and less affected by efflux and porins
	**Enterobacterales, including many ESBLs		**Enterobacterales, including many ESBLs
	***Activity against AmpC organisms is variable (50% for [[Enterobacter]] vs 97% for [[Escherichia coli]])		***Activity against AmpC organisms is variable (50% for [[Enterobacter]] vs 97% for [[Escherichia coli]])
Line 30:		Line 30:
	*No significant drug-drug interactions		*No significant drug-drug interactions

	== Dosing ==		==Dosing==

	* Urinary tract and intraabdominal infection: ceftolozane-tazobactam 1.5 g (1 g / 0.5 g) IV q8h		*Urinary tract and intraabdominal infection: ceftolozane-tazobactam 1.5 g (1 g / 0.5 g) IV q8h
	* Pneumonia: ceftolozane-tazobactam 3 g IV q8h		*Pneumonia: ceftolozane-tazobactam 3 g IV q8h

	==Safety==		==Safety==

Aidan at 13:38, 12 September 2020

2020-09-12T13:38:52Z

← Older revision		Revision as of 13:38, 12 September 2020
Line 1:		Line 1:
	== Background ==		==Background==

	*Novel antipseudomonal antibiotic		*Novel antipseudomonal antibiotic

	=== Mechanism of Action ===		===Mechanism of Action===

	*Structure is similar to [[ceftazidime]], but with C3 substitution		*Structure is similar to [[ceftazidime]], but with C3 substitution
	*[[Ceftolozane]] is stable against AmpC β-lactamases and is somewhat resistant to efflux pumps and		*[[Ceftolozane]] is stable against AmpC β-lactamases and is somewhat resistant to efflux pumps and
	*[[Tazobactam]] is active against most class A and some class C β-lactamases		*[[Tazobactam]] is active against most class A and some class C β-lactamases
	*Bactericidal		*Bactericidal

	=== Acitivity ===		===Acitivity===

	*GNB:		*GNB:
Line 22:		Line 22:
	*Variable against anaerobes		*Variable against anaerobes

			===Pharmacokinetics and Pharmacodynamics===
	=== PK/PD ===

	*Half-life about 2.5 hours		*Half-life about 2.5 hours
Line 30:		Line 30:
	*No significant drug-drug interactions		*No significant drug-drug interactions

	=== ~~Safety~~ ===		== Dosing ==

			* Urinary tract and intraabdominal infection: ceftolozane-tazobactam 1.5 g (1 g / 0.5 g) IV q8h
			* Pneumonia: ceftolozane-tazobactam 3 g IV q8h

			==Safety==

	*Adverse events similar to other cephalosporins		*Adverse events similar to other cephalosporins
	*GI effects, [[Clostridioides difficile]], liver enzymes		*GI effects, [[Clostridioides difficile]], liver enzymes

	=== Evidence ===		==Evidence==

	*ASPECT-cIAI: complicated intraabdo infections with metronidazole		*ASPECT-cIAI: complicated intraabdo infections with metronidazole

Aidan at 14:04, 26 August 2020

2020-08-26T14:04:00Z

← Older revision		Revision as of 14:04, 26 August 2020
Line 47:		Line 47:
	**Compared to meropenem		**Compared to meropenem

	[[Category:~~Antibiotics~~]]		[[Category:Cephalosporins]]
	[[Category:~~Infectious~~ ~~diseases~~]]		[[Category:β-lactamase inhibitors]]

Aidan at 13:24, 26 August 2020

2020-08-26T13:24:11Z

← Older revision		Revision as of 13:24, 26 August 2020
Line 1:		Line 1:
			== Background ==
	*Antipseudomonal antibiotic

⚫	*[[Ceftolozane]] is stable against AmpC β-lactamases and is somewhat resistant to efflux
			*Novel antipseudomonal antibiotic

			=== Mechanism of Action ===

			*Structure is similar to [[ceftazidime]], but with C3 substitution
		⚫	*[[Ceftolozane]] is stable against AmpC β-lactamases and is somewhat resistant to efflux pumps and
	*[[Tazobactam]] is active against most class A and some class C β-lactamases		*[[Tazobactam]] is active against most class A and some class C β-lactamases
			*Bactericidal

			=== Acitivity ===

			*GNB:
			**MDRPsA with less affinity for Pseudomonal AmpC and less affected by efflux and porins
			**Enterobacterales, including many ESBLs
			***Activity against AmpC organisms is variable (50% for [[Enterobacter]] vs 97% for [[Escherichia coli]])
			**Not active against carbapenemase-producing organisms
			**Limited activity against Oxa-48
			**Limited activity against [[Acinetobacter species]] and [[Stenotrophomonas maltophilia]]
			*GPC: possibly active against Strep pneumo and pyogenes, but none against Staph and Enterococcus
			*Variable against anaerobes

			=== PK/PD ===

			*Half-life about 2.5 hours
			*Protein binding 20%
			*Good penetration into lung
			*Renally cleared
			*No significant drug-drug interactions

			=== Safety ===

			*Adverse events similar to other cephalosporins
			*GI effects, [[Clostridioides difficile]], liver enzymes

			=== Evidence ===

			*ASPECT-cIAI: complicated intraabdo infections with metronidazole
			**Solomkin CID 2015;60:1462-1471
			**Compared to meropenem
			*ASPECT-cUTI: complicated UTI
			**Wagenlehner Lancet 2015;385:1949-1956
			**Compared to levofloxacin
			*ASPECT-NP: nosocomial pneumonia
			**Kolleff Lancet ID 2019;19:1299
			**Compared to meropenem

	[[Category:Antibiotics]]		[[Category:Antibiotics]]

Aidan at 14:00, 15 August 2020

2020-08-15T14:00:33Z

← Older revision		Revision as of 14:00, 15 August 2020
Line 1:		Line 1:
	* Antipseudomonal antibiotic		*Antipseudomonal antibiotic
	* [[Ceftolozane]] is stable against AmpC β-lactamases		*[[Ceftolozane]] is stable against AmpC β-lactamases and is somewhat resistant to efflux
			*[[Tazobactam]] is active against most class A and some class C β-lactamases

			[[Category:Antibiotics]]
			[[Category:Infectious diseases]]

Aidan: Created page with "* Antipseudomonal antibiotic * Ceftolozane is stable against AmpC β-lactamases"

2020-08-15T13:58:59Z

Created page with "* Antipseudomonal antibiotic * Ceftolozane is stable against AmpC β-lactamases"

New page

* Antipseudomonal antibiotic
* [[Ceftolozane]] is stable against AmpC β-lactamases